These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22289724)

  • 1. Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline.
    Vaidyanathan S; Williamson P; Lipworth B
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):77-80. PubMed ID: 22289724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
    Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
    Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal airway resistance after decongestion with a nasal spray or a bellows device.
    Jessen M; Ivarsson A; Malm L
    Rhinology; 1996 Mar; 34(1):28-31. PubMed ID: 8739865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.
    Vaidyanathan S; Williamson P; Clearie K; Khan F; Lipworth B
    Am J Respir Crit Care Med; 2010 Jul; 182(1):19-24. PubMed ID: 20203244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion.
    Morris S; Eccles R; Martez SJ; Riker DK; Witek TJ
    Am J Rhinol; 1997; 11(2):109-15. PubMed ID: 9129752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The observation of the ciliotoxicity of nasal mucosa with nasal decongestant].
    Teng Y; Zhang X; Xu G; Cai Q; Xu J
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Sep; 19(18):824-6. PubMed ID: 16375111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superficial nasal mucosal blood flow and nasal patency following topical oxymetazoline hydrochloride.
    Witek TJ; Canestrari DA; Hernandez JR; Miller RD; Yang JY; Riker DK
    Ann Allergy; 1992 Feb; 68(2):165-8. PubMed ID: 1739191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis.
    Valerieva A; Popov TA; Staevska M; Kralimarkova T; Petkova E; Valerieva E; Mustakov T; Lazarova T; Dimitrov V; Church MK
    Allergy Asthma Proc; 2015; 36(6):e134-9. PubMed ID: 26133030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of oxymetazoline in nasal endoscopic sinus surgery].
    Zhen H; Gao Q; Cui Y; Hua X; Li H; Feng J
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 May; 17(5):281-2. PubMed ID: 12916356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of peak nasal inspiratory flowmetry and nasal decongestant to evaluate outcome of septoplasty with radiofrequency coblation of the inferior turbinate.
    Balikci HH; Gurdal MM
    Rhinology; 2014 Jun; 52(2):112-115. PubMed ID: 24932620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oxymetazoline on nasal and sinus mucosal blood flow in the rabbit as measured with laser-Doppler flowmetry.
    Akerlund A; Arfors KE; Bende M; Intaglietta M
    Ann Otol Rhinol Laryngol; 1993 Feb; 102(2):123-6. PubMed ID: 8427497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peak nasal inspiratory flow and Wright peak flow: a comparison of their reproducibility.
    Enberg RN; Ownby DR
    Ann Allergy; 1991 Sep; 67(3):371-4. PubMed ID: 1897817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant.
    Ferguson EA; Eccles R
    Acta Otolaryngol; 1997 Jul; 117(4):614-7. PubMed ID: 9288222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peak nasal inspiratory flow--the plateau effect.
    Clarke RW; Jones AS; Richardson H
    J Laryngol Otol; 1995 May; 109(5):399-402. PubMed ID: 7541066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between nasal cavity volume changes and nasalance.
    Birkent H; Erol U; Ciyiltepe M; Eadie TL; Durmaz A; Tosun F
    J Laryngol Otol; 2009 Apr; 123(4):407-11. PubMed ID: 19000331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoker's nose: structural and functional characteristics.
    Kjaergaard T; Cvancarova M; Steinsvaag SK
    Laryngoscope; 2010 Jul; 120(7):1475-80. PubMed ID: 20564717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of anterior rhinomanometry in diode laser turbinoplasty.
    Volk GF; Pantel M; Guntinas-Lichius O; Wittekindt C
    Arch Otolaryngol Head Neck Surg; 2010 Oct; 136(10):1015-9. PubMed ID: 20956750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults.
    Taverner D; Bickford L; Shakib S; Tonkin A
    Eur J Clin Pharmacol; 1999 Sep; 55(7):509-13. PubMed ID: 10501820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours.
    Druce HM; Ramsey DL; Karnati S; Carr AN
    Rhinology; 2018 Dec; 56(4):343-350. PubMed ID: 29785414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis.
    Baroody FM; Brown D; Gavanescu L; DeTineo M; Naclerio RM
    J Allergy Clin Immunol; 2011 Apr; 127(4):927-34. PubMed ID: 21377716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.